Kimchi and Cancer by Dr. Joseph C. Kim

Background: Understanding the burden of comorbidities in patients with gastric cancer may aid in treatment planning and evaluating the safety of new treatments. Methods: Using the Surveillance, Epidemiology, and End Results (SEER)–Medicare combined dataset, we identified 12,612 patients diagnosed with gastric cancer 2000–2007. A cohort of 12,612 cancer-free individuals was frequency-matched by Medicare enrollment year and county of residence. Subjects were ≥66 years-old at index date to allow for ≥1 full year of Medicare coverage. Prevalence the year before index date and 3- and 12-month incidence rates (per 100 person-years) after index date were estimated for 42 common comorbidities. Results: Comorbidities with the highest (≥8%) 3-month incidence in patients with gastric cancer are shown. Conclusions: Comorbidity prevalence before index date was modestly higher, and incidence rates after index date were much higher in gastric cancer patients than in cancer-free individuals. The poten

Stomach cancer is also called gastric cancer. If you're thinking of colon cancer, yes - the colon is in your abdomen (belly), but it's not the stomach. The liver is also in your belly, but it's not your stomach. Gastric cancer is also called gastric carcinoma. FDA Approves Ramucirumab for Stomach Cancer The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy. Ramucirumab is a recombinant monoclonal antibody of the IgG1 class that binds to the vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks the activation of the receptor.